Viewing Study NCT05607550

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 4:50 PM

Ignite Modification Date: 2025-12-28 @ 9:17 AM

Study NCT ID: NCT05607550

Status: ACTIVE_NOT_RECRUITING

Last Update Posted: 2025-06-22

First Post: 2022-10-31

Is NOT Gene Therapy: True

Has Adverse Events: False

Brief Title: Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Sponsor: ArriVent BioPharma, Inc.

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module